BeiGene (STU:49B) Retained Earnings : €-8,220 Mil (As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is BeiGene Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. BeiGene's retained earnings for the quarter that ended in Dec. 2024 was €-8,220 Mil.

BeiGene's quarterly retained earnings increased from Jun. 2024 (€-7,742 Mil) to Sep. 2024 (€-7,618 Mil) but then declined from Sep. 2024 (€-7,618 Mil) to Dec. 2024 (€-8,220 Mil).

BeiGene's annual retained earnings declined from Dec. 2022 (€-6,684 Mil) to Dec. 2023 (€-7,301 Mil) and declined from Dec. 2023 (€-7,301 Mil) to Dec. 2024 (€-8,220 Mil).

BeiGene Retained Earnings Historical Data

The historical data trend for BeiGene's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BeiGene Retained Earnings Chart

BeiGene Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Retained Earnings

Get a 7-Day Free Trial

-2,920.36

-4,492.73

-6,683.84

-7,301.20

-8,219.53

BeiGene Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Retained Earnings	Get a 7-Day Free Trial															-7,301.20	-7,556.14	-7,741.92	-7,617.91	-8,219.53

BeiGene Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

BeiGene (STU:49B) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

BeiGene Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BeiGene Ltd (STU:49B) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

ONC:USA 06160:Hong Kong 688235:China B1ME34:Brazil

Address

c/o Mourant Governance Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, Grand Cayman, CYM, KY1-1108

Website

https://www.beigene.com

Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene's revenue.

BeiGene Headlines

No Headlines